Biotek Salon #25 : Value creation in Life Sciences

Two biotech companies A and B can have the same market cap/pre-money but very different price per share and it’s the latter that determines the value creation.

Welcome to this session on Value creation in Life Sciences provided by Saurabh Mishra, Founder and Managing Partner of Farmantra.

There are no black and white strategies for value creation, but most of them depend on the following:

• Under-capitalize or Over capitalize: Why raising the “right” amount is the key to capital efficiency?
• License or Build – Does partnership with Pharma provide 100% non-dilutive money?
• Dilutive vs Non-dilutive funding: How do you balance the risks?
• Product vs Platform companies: What drives value?
• Biotech market crash: What fundamentals matter during these times? How can we manage risks through non-predictive decision making?

Farmantra will share couple of case studies of few successful biotech companies to align with the above thinking.